此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

MUltiple Sclerosis : T Cell / B Cell Exploration (MUST-BE)

2021年12月1日 更新者:Rennes University Hospital

T Cell/B Cell Collaboration in Multiple Sclerosis: Exploring an Intimate Relationship

This study, an ancillary to ABCD-SEP (NCT03744351), will be interested in more precisely characterizing circulating and infiltrating TH cells in Multiple Sclerosis whether at the transcriptomic level or at the functional level.

研究概览

地位

完全的

详细说明

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the Central Nervous System (CNS) affecting mostly young adults between 20 and 40 years of age. This disease is the leading cause of non-traumatic disability in young adults.

MS has long been considered a predominantly T-cell mediated disease. However, the remarkable efficacy of anti-CD20 monoclonal antibodies in this disease has demonstrated the major role of B-cell in the pathophysiology of this disease.

The B-cell have many functions: these cells are indeed able to secrete cytokines (pro and anti inflammatory), to present antigens to T lymphocytes, but also to differentiate into plasmocytic cells and thus to secrete immunoglobulins. Several studies have shown that B-cell in patients with MS secrete significantly more pro-inflammatory cytokines (GM-CSF, IL-6, TNFα). In addition, infiltrates and tertiary lymphoid structures have been found in the meninges of patients with MS, particularly in progressive forms of the disease. It seems clear to this day that these cells are strongly involved in the development of MS. Despite the many advances made recently in understanding the role of B-cell in the pathophysiology of MS, the precise involvement of plasma cells and their functions at different stages of the disease remains unclear.

Folluclar helper T cells (TFH) play a crucial role in lymphocyte B differentiation. These cells are located within the germinal centers in the secondary lymphoid organs, and their memory compartment also circulates in the blood. Several circulating TFH subpopulations have recently been defined, with different "helping" capacities.

This study, an ancillary to ABCD-SEP (NCT03744351), will be interested in more precisely characterizing circulating and infiltrating TH cells in Multiple Sclerosis whether at the transcriptomic level or at the functional level.

研究类型

观察性的

注册 (实际的)

90

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Rennes、法国、35033
        • Rennes University Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

The population concerned is the same as the one participating in the ABCD-SEP study.

These patients gave their consent for the remaining biological samples to be used for ulterior research

描述

Inclusion Criteria:

Regarding MS patients (remitting or progressive untreated):

  • Adult (age greater than or equal to 18 years) of both sexes;
  • MS fulfilling the criteria of McDonald 2017;
  • Remittent or progressive form;
  • No immunomodulatory or immunosuppressive therapy for at least 3 months;
  • Free, informed and written consent signed by the patient.

Regarding Clinically Isolated Syndrome:

  • Adult (age greater than or equal to 18 years) of both sexes;
  • Clinically isolated syndrome suggestive of MS (at least two typical lesions in two different locations);
  • Patient receiving a Lumbar Puncture (PL) for diagnostic purposes;
  • No immunomodulatory or immunosuppressive therapy for at least 3 months;
  • Free, informed and written consent signed by the patient.

Regarding non-MS patients with neurological inflammatory disease:

  • Adult (age greater than or equal to 18 years) of both sexes;
  • Patient with non-MS neurological inflammatory disease (examples: meningitis, neurolupus, neurosarcoidosis...);
  • Patients with PL for diagnostic or surveillance purposes;
  • No immunomodulatory or immunosuppressive therapy for at least 3 months;
  • Free, informed and written consent signed by the patient.

Regarding healthy volunteers:

  • Adult (age greater than or equal to 18 years) of both sexes;
  • Free, informed and written consent signed by the volunteer.

Exclusion Criteria:

Regarding all patients:

  • Pregnancy;
  • Breastfeeding;
  • Treatment with corticotherapy in the last month;
  • Patient not affiliated to health insurance;
  • Persons major subject to legal protection (safeguard of justice, guardianship, tutorship), persons deprived of their liberty.

Regarding healthy volunteers:

  • Pregnancy;
  • Breastfeeding;
  • Not affiliated to social security;
  • Persons major subject to legal protection (safeguard of justice, guardianship, tutorship), persons deprived of their liberty.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
To compare the transcriptome profile of infiltrating TFH cells from CIS patients to non-MS patients with neurological inflammatory diseases
大体时间:At inclusion
Comparison of each gene expression of infiltrating TFH cells from CIS patients to those of non-MS patients with neurological inflammatory diseases by RNAsequencing
At inclusion

次要结果测量

结果测量
措施说明
大体时间
To compare the transcriptome profile of infiltrating TFH cells from CIS patients to healthy volunteers.
大体时间:At inclusion
Comparison of each gene expression of infiltrating TFH cells from CIS patients to those of healthy volunteers (HV) by RNAsequencing
At inclusion
To compare the B cell differentiation helping abilities of TFH cells from MS patients to those of HV
大体时间:At inclusion
Analysis of B cell phenotype after 7 days of in vitro coculture assays and comparison of the frequencies between MS patients and HV
At inclusion
To compare the migration abilities of TFH cells from MS patients to those of HV
大体时间:At inclusion
Analysis of the rate, number and phenotype of migrating TFH cells after 12 to 24 hours using an in vitro model of Blood Brain Barrier in MS patients compared to HV
At inclusion

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Laure Michel、Rennes University Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年2月25日

初级完成 (实际的)

2021年10月31日

研究完成 (实际的)

2021年10月31日

研究注册日期

首次提交

2020年1月13日

首先提交符合 QC 标准的

2020年1月13日

首次发布 (实际的)

2020年1月18日

研究记录更新

最后更新发布 (实际的)

2021年12月2日

上次提交的符合 QC 标准的更新

2021年12月1日

最后验证

2021年12月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅